Plain-English translation of NCT07091305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called QL1706 that works against two different immune system targets (PD-1 and CTLA-4). You would receive this medication combined with chemotherapy drugs over several rounds, followed by radiation therapy, and then more of the medication alone. The trial wants to see if this approach helps people with limited-stage small cell lung cancer live longer and stay cancer-free.
Small cell lung cancer is an aggressive form of cancer that comes back quickly even after standard treatment. This medication is designed to boost your immune system's ability to fight cancer cells, and researchers want to find out if adding this treatment alongside or after standard chemotherapy and radiation can improve outcomes for patients with this disease.
You likely qualify if…
You likely don't qualify if…
You would first receive the new medication combined with chemotherapy drugs every three weeks for several rounds. After this induction phase, you would undergo standard radiation therapy combined with chemotherapy, followed by more rounds of the medication alone as consolidation treatment. Throughout the trial, you would have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and to check for any side effects. The entire treatment course would take several months.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China